These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 8325202)
1. Hypersensitivity to insulin during remissions in cyclosporin-treated IDDM patients. Burcelin RG; Eddouks M; Beylot M; Normand S; Boitard C; Feutren G; Landais P; Riou JP; Girard JR; Bach JF Diabetes Care; 1993 Jun; 16(6):881-8. PubMed ID: 8325202 [TBL] [Abstract][Full Text] [Related]
2. Natural course of remission in IDDM during 1st yr after diagnosis. Martin S; Pawlowski B; Greulich B; Ziegler AG; Mandrup-Poulsen T; Mahon J Diabetes Care; 1992 Jan; 15(1):66-74. PubMed ID: 1737543 [TBL] [Abstract][Full Text] [Related]
3. Long-term results of early cyclosporin therapy in juvenile IDDM. De Filippo G; Carel JC; Boitard C; Bougnères PF Diabetes; 1996 Jan; 45(1):101-4. PubMed ID: 8522052 [TBL] [Abstract][Full Text] [Related]
4. Cyclosporin A does not delay insulin dependency in asymptomatic IDDM patients. Rakotoambinina B; Timsit J; Deschamps I; Laborde K; Jos J; Boitard C; Assan R; Robert JJ Diabetes Care; 1995 Nov; 18(11):1487-90. PubMed ID: 8722075 [TBL] [Abstract][Full Text] [Related]
5. Seven years of remission in a type I diabetic patient. Koivisto VA; Leirisalo-Repo M; Ebeling P; Tuominen JA; Knip M; Turunen U; Mandrup-Poulsen T; Pelkonen R Diabetes Care; 1993 Jul; 16(7):990-5. PubMed ID: 8359107 [TBL] [Abstract][Full Text] [Related]
6. Cellular and humoural autoimmunity markers in type 2 (non-insulin-dependent) diabetic patients with secondary drug failure. Zavala AV; Fabiano de Bruno LE; Cardoso AI; Mota AH; Capucchio M; Poskus E; Fainboim L; Basabe JC Diabetologia; 1992 Dec; 35(12):1159-64. PubMed ID: 1478368 [TBL] [Abstract][Full Text] [Related]
7. Antibodies to glutamic acid decarboxylase and insulin-dependent diabetes in patients with autoimmune polyendocrine syndrome type I. Tuomi T; Björses P; Falorni A; Partanen J; Perheentupa J; Lernmark A; Miettinen A J Clin Endocrinol Metab; 1996 Apr; 81(4):1488-94. PubMed ID: 8636356 [TBL] [Abstract][Full Text] [Related]
8. Lack of predictive value of islet cell antibodies, insulin antibodies, and HLA-DR phenotype for remission in cyclosporin-treated IDDM patients. The Canadian-European Randomized Control Trial Group. Mandrup-Poulsen T; Mølvig J; Andersen HU; Helqvist S; Spinas GA; Munck M Diabetes; 1990 Feb; 39(2):204-10. PubMed ID: 2227128 [TBL] [Abstract][Full Text] [Related]
9. Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin. Bougnères PF; Landais P; Boisson C; Carel JC; Frament N; Boitard C; Chaussain JL; Bach JF Diabetes; 1990 Oct; 39(10):1264-72. PubMed ID: 2210078 [TBL] [Abstract][Full Text] [Related]
10. Altered immune response to insulin in newly diagnosed compared to insulin-treated diabetic patients and healthy control subjects. Schloot NC; Roep BO; Wegmann D; Yu L; Chase HP; Wang T; Eisenbarth GS Diabetologia; 1997 May; 40(5):564-72. PubMed ID: 9165225 [TBL] [Abstract][Full Text] [Related]
11. "Lady-like": is there a latent autoimmune diabetes in the young? Lohmann T; Nietzschmann U; Kiess W Diabetes Care; 2000 Nov; 23(11):1707-8. PubMed ID: 11092301 [No Abstract] [Full Text] [Related]
12. Natural course of insulin sensitivity and insulin reserve in early insulin-dependent diabetes mellitus. Linn T; Ebener K; Raptis G; Laube H; Federlin K Metabolism; 1995 May; 44(5):617-23. PubMed ID: 7752910 [TBL] [Abstract][Full Text] [Related]
13. Immunogenetic and clinical characterization of slowly progressive IDDM. Kobayashi T; Tamemoto K; Nakanishi K; Kato N; Okubo M; Kajio H; Sugimoto T; Murase T; Kosaka K Diabetes Care; 1993 May; 16(5):780-8. PubMed ID: 8098691 [TBL] [Abstract][Full Text] [Related]
14. Immunogenetic and nutritional profile in insulin-using youth-onset diabetics in Korea. Huh KB; Lee HC; Kim HM; Cho YW; Kim YL; Lee KW; Lee EJ; Lim SK; Kim DH; Yoon JW Diabetes Res Clin Pract; 1992 Apr; 16(1):63-70. PubMed ID: 1576933 [TBL] [Abstract][Full Text] [Related]
15. Plasma C-peptide levels and clinical remissions in recent-onset type I diabetic patients treated with cyclosporin A and insulin. Assan R; Feutren G; Sirmai J; Laborie C; Boitard C; Vexiau P; Du Rostu H; Rodier M; Figoni M; Vague P Diabetes; 1990 Jul; 39(7):768-74. PubMed ID: 2191883 [TBL] [Abstract][Full Text] [Related]
16. Anti-bovine serum albumin antibodies: genetic heterogeneity and clinical relevance in adult-onset IDDM. Krokowski M; Caillat-Zucman S; Timsit J; Larger E; Pehuet-Figoni M; Bach JF; Boitard C Diabetes Care; 1995 Feb; 18(2):170-3. PubMed ID: 7729293 [TBL] [Abstract][Full Text] [Related]
17. IA-2 antibody-negative status predicts remission and recovery of C-peptide levels in type 1 diabetic patients treated with cyclosporin. Christie MR; Mølvig J; Hawkes CJ; Carstensen B; Mandrup-Poulsen T; Diabetes Care; 2002 Jul; 25(7):1192-7. PubMed ID: 12087018 [TBL] [Abstract][Full Text] [Related]
18. Relationships among 64k autoantibodies, pancreatic beta-cell function, HLA-DR antigens and HLA-DQ genes in patients with insulin-dependent diabetes mellitus in Korea. Lee HC; Cha BS; Nam MS; Song YD; Lim SK; Kim DH; Huh KB; Koh Y Korean J Intern Med; 1995 Jan; 10(1):1-9. PubMed ID: 7626550 [TBL] [Abstract][Full Text] [Related]
19. Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. The Canadian-European Randomized Control Trial Group. Diabetes; 1988 Nov; 37(11):1574-82. PubMed ID: 2903105 [TBL] [Abstract][Full Text] [Related]
20. Parameters associated with residual insulin secretion during the first year of disease in children and adolescents with Type 1 diabetes mellitus. Bonfanti R; Bazzigaluppi E; Calori G; Riva MC; Viscardi M; Bognetti E; Meschi F; Bosi E; Chiumello G; Bonifacio E Diabet Med; 1998 Oct; 15(10):844-50. PubMed ID: 9796885 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]